Compare JD.Com Inc (JD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Twist Bioscience Corp — how do they compare? JD.Com Inc trades at $30.81 (market cap $41.80B), while Twist Bioscience Corp trades at $93.5 (market cap $5.45B). The key difference: JD.Com Inc is far larger — about 7.7× Twist Bioscience Corp's market cap, and JD.Com Inc pays a 3.27% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| JD | TWST | |
|---|---|---|
Market Cap | $41.80B | $5.45B |
Sector | Consumer Cyclical | Health |
52-Week High | $36.17 | $102.88 |
52-Week Low | $25.19 | $24.16 |
Enterprise Value | $27.96B | $5.37B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $30.60, up 3.31% with strong recent earnings beats. The stock shows bullish technical signals with moving averages supporting upside, while RSI levels indicate potential overbought conditions. Fundamentally, revenue grew to $1.31 trillion in 2025, though net income margin compressed to 1.05%. Analyst consensus remains strongly bullish with a $39.50 price target, representing significant upside potential from current levels.
JD offers attractive valuation with P/S of 0.22 and P/E of 21.75, but faces risks from Chinese regulatory environment and ongoing margin pressure. The company maintains robust cash flow generation and shareholder returns through buybacks. Near-term catalyst includes Q2 2026 earnings release with expected EPS of $0.86.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
